BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 27813153)

  • 1. TRAF6 Mediates Suppression of Osteoclastogenesis and Prevention of Ovariectomy-Induced Bone Loss by a Novel Prenylflavonoid.
    Tan EM; Li L; Indran IR; Chew N; Yong EL
    J Bone Miner Res; 2017 Apr; 32(4):846-860. PubMed ID: 27813153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways.
    Xiao L; Zhong M; Huang Y; Zhu J; Tang W; Li D; Shi J; Lu A; Yang H; Geng D; Li H; Wang Z
    Aging (Albany NY); 2020 Nov; 12(21):21706-21729. PubMed ID: 33176281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Osteoclastogenesis and Bone Resorption in vitro and in vivo by a prenylflavonoid xanthohumol from hops.
    Li J; Zeng L; Xie J; Yue Z; Deng H; Ma X; Zheng C; Wu X; Luo J; Liu M
    Sci Rep; 2015 Dec; 5():17605. PubMed ID: 26620037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
    Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
    Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioactive iron oxide nanoparticles suppress osteoclastogenesis and ovariectomy-induced bone loss through regulating the TRAF6-p62-CYLD signaling complex.
    Liu L; Jin R; Duan J; Yang L; Cai Z; Zhu W; Nie Y; He J; Xia C; Gong Q; Song B; Anderson JM; Ai H
    Acta Biomater; 2020 Feb; 103():281-292. PubMed ID: 31866569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis.
    Chen X; Zhi X; Pan P; Cui J; Cao L; Weng W; Zhou Q; Wang L; Zhai X; Zhao Q; Hu H; Huang B; Su J
    FASEB J; 2017 Nov; 31(11):4855-4865. PubMed ID: 28739641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways.
    Yin Z; Zhu W; Wu Q; Zhang Q; Guo S; Liu T; Li S; Chen X; Peng D; Ouyang Z
    Eur J Pharmacol; 2019 Sep; 859():172550. PubMed ID: 31323222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
    Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
    PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
    Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
    Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis.
    Kim M; Kim HS; Kim JH; Kim EY; Lee B; Lee SY; Jun JY; Kim MB; Sohn Y; Jung HS
    BMC Complement Med Ther; 2020 Feb; 20(1):35. PubMed ID: 32024503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guaiacol suppresses osteoclastogenesis by blocking interactions of RANK with TRAF6 and C-Src and inhibiting NF-κB, MAPK and AKT pathways.
    Zhi X; Fang C; Gu Y; Chen H; Chen X; Cui J; Hu Y; Weng W; Zhou Q; Wang Y; Wang Y; Jiang H; Li X; Cao L; Chen X; Su J
    J Cell Mol Med; 2020 May; 24(9):5122-5134. PubMed ID: 32185887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
    Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
    Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
    Hu B; Sun X; Yang Y; Ying Z; Meng J; Zhou C; Jiang G; Li S; Wu F; Zhao X; Zhu H; Wu H; Cai X; Shi Z; Yan S
    FASEB J; 2019 Feb; 33(2):2574-2586. PubMed ID: 30285579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α.
    Wang L; Qiu XM; Gui YY; Xu YP; Gober HJ; Li DJ
    Drug Des Devel Ther; 2015; 9():3755-66. PubMed ID: 26229438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats.
    Peng S; Zhang G; Zhang BT; Guo B; He Y; Bakker AJ; Pan X; Zhen W; Hung L; Qin L; Leung WN
    Bone; 2013 Jul; 55(1):230-40. PubMed ID: 23486180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.